Episode
Episode 171 - Amin & Chad - Resvita Bio CEO & CTO
- Podcast
- The BioHub - by Avetix
- Published
- May 11, 2026
- Duration seconds
- 2025
- Processing state
not_requested- Canonical source
- https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-171---Amin--Chad---Resvita-Bio-CEO--CTO-e3j6khp
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-171-amin-chad-resvita-bio-ceo-cto/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-171-amin-chad-resvita-bio-ceo-cto.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast , Max sits down with Amin Zargar, CEO of ResVita Bio, and Chad Miller, the company’s Chief Technology Officer. ResVita is developing a new class of treatments for skin diseases using engineered bacteria to deliver continuous protein therapy directly on the skin — an approach designed to transform how chronic dermatological conditions are treated. Amin brings deep expertise in synthetic biology from Jay Keasling’s lab at UC Berkeley, while Chad’s background spans protein design research in David Baker’s lab and founding Nosis Bio. In this conversation, we talk about how ResVita was founded, the science behind continuous protein therapy, why Chad joined the mission, and what’s next as the company moves toward the clinic.